U s vaccine market industry analysis, trends and forecast 2014 2020

Transparency Market Research U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Published Date 27-Jan-2015

83 Page Report

Buy Now

Request Sample

Press Release

U.S. Vaccine Market to Expand at 4.3% CAGR from 2014 to 2020, Initiatives to Eradicate Lethal Diseases Drive Market

Transparency Market Research State Tower, 90, State Street, Suite 700.

Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

U.S. Vaccine Market

REPORT DESCRIPTION

U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 Transparency Market Research has published a report on the U.S. vaccine market for the 2014-2020 period.

According to the report, this market will expand at a CAGR of 4.3% between 2014 and 2020. This report on the U.S. vaccine market presents an insightful and in-depth overview of the current and future growth potential of the human and animal vaccine markets. The title of this report is “U.S. Vaccine Market Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020� and is available for sale on the company’s website.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/us-vaccine-market.html A vaccine is a biological preparation that delivers active acquired immunity against a particular disease. It is administered either through needle injections, orally, or by aerosol. Vaccination involves the administration of a killed or weakened organism into the body that develops immunity in the body against that organism. Vaccines cause immunization; there are also some diseases that provide immunization after recovery from the disease.

According to the Centers for Disease Control and Prevention (CDC), vaccination programs across the U.S. have been successful in the eradication of lethal diseases such as polio, smallpox, and diphtheria, while diseases such as tetanus, rubella, and measles have been largely controlled. Vaccination administered as a preventive measure has helped save the lives of millions of individuals in the U.S. In the U.S., strict regulations imposed by the federal government, which mandate immunization against certain diseases is driving the U.S. vaccines market. Meanwhile, the rising incidence of zoonotic diseases among animals and the high risk of transmitting its associated infection to humans is propelling the growth of the animal vaccines market. Moreover, widespread pet ownership in the country has significantly contributed to the growth of the animal vaccines market in the U.S. Factors such as the rising consumption of poultry and meat products and recent approvals of Prime Pac PRRS+ and Once PMH IN have also bolstered the growth of the U.S. animal vaccine market.

On the flip side, the stringent regulatory framework that governs the approval process of vaccines in the U.S. impedes the growth of this market to a certain extent. Moreover, the high cost involved in the

Transparency Market Research

2

U.S. Vaccine Market

research and development of new vaccines will also hamper the growth of this market during the forecast period.

The report segments the U.S. vaccine market into human vaccines and animal vaccine to analyze this market during the forecast period. By vaccine type, the U.S. human vaccine market is divided into adult and pediatric vaccines. By antigen, this market is divided into hepatitis, meningococcal, human papillomavirus (HPV), influenza, pneumococcal, combination vaccines, and others.

Downlaod Brochure: http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=553 The U.S. market for animal vaccines is segmented into companion animal and livestock vaccines. The companion animal vaccines segment is further sub-segmented into canine and feline. In 2013, canine vaccines held a slightly larger share than feline vaccines due to the higher average cost of canine vaccines.

Some of the leading players in the U.S. vaccines market are Novartis International AG, Merck & Co. Inc., Sanofi, GlaxoSmithKline plc, and Merck & Co. The U.S. vaccine market is segmented as follows: U.S. Human Vaccine Market, by Type •

Pediatric

•

Adult

U.S. Human Vaccine Market, by Antigen •

Hepatitis (A & B)

•

Influenza

•

Meningococcal

•

Pneumococcal

•

Human Papillomavirus (HPV)

Transparency Market Research

3

U.S. Vaccine Market

•

Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)

•

Others

U.S. Animal Vaccine Market, by Animal Type •

•

Companion Animal Vaccine Market ◦

Canine

◦

Feline

Livestock Vaccine Market ◦

Porcine

◦

Bovine

◦

Ovine

◦

Poultry

◦

Equine

TABLE OF CONTENT

Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Assumptions 1.3.2 Sources 1.3.2.1 Secondary Research

Transparency Market Research

4

U.S. Vaccine Market

1.3.2.2 Primary Research 1.3.3 Models

Chapter 2 Executive Summary 2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020) 2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)

Chapter 3 U.S. Vaccine Market Overview 3.1 Introduction 3.2 Vaccine Approval Regulatory Pathway 3.2.1 Major Steps: Vaccine Development and Commercialization 3.3 Drivers 3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination 3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S. 3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines 3.3.4 Education and awareness through various governmental and non-profit organizations 3.4 Restraints 3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development 3.4.2 High cost associated with vaccine transportation, storage and handling 3.5 Opportunities 3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases 3.5.2 The U.S. offers immense potential for adult vaccines market 3.6 Competitive Landscape

Transparency Market Research

5

U.S. Vaccine Market

3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %) 3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)

Chapter 4 U.S. Human Vaccine Market Revenue 4.1 Overview 4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million) 4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million) 4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %) 4.1.4 Hepatitis 4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.5 Influenza 4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.6 Meningococcal 4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.7 Pneumococcal 4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.8 Human Papillomavirus (HPV) 4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.9 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) 4.1.9.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.10 Others 4.1.10.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.2 Pricing Analysis 4.2.1 Pricing Analysis: Hepatitis Vaccines

Transparency Market Research

6

U.S. Vaccine Market

4.2.2 Pricing Analysis: Influenza Vaccines 4.2.3 Pricing Analysis: Meningococcal Vaccines 4.2.4 Pricing Analysis: Pneumococcal Vaccines 4.2.5 Pricing Analysis: Human Papillomavirus Vaccines (HPV) 4.2.6 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) 4.2.7 Pricing Analysis: Other Vaccines

Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.1 Overview 5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million) 5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %) 5.2 Companion Animal Vaccines 5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.2.2 Canine Vaccines 5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.2.2.2 Pricing Analysis: Canine Vaccines 5.2.3 Feline Vaccines 5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.2.3.2 Pricing Analysis: Feline Vaccines 5.3 Livestock Vaccines 5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.3.2 Porcine Vaccines 5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)

Transparency Market Research

7

U.S. Vaccine Market

5.3.2.2 Pricing Analysis: Porcine Vaccines 5.3.3 Bovine Vaccines 5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.3.2 Pricing Analysis: Bovine Vaccines 5.3.4 Ovine Vaccines 5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.4.2 Pricing Analysis: Ovine Vaccines 5.3.5 Poultry Vaccines 5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.6 Equine Vaccines 5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.6.2 Pricing Analysis: Equine Vaccines Chapter 6 Recommendations 6.1 Focus on cost-effective vaccine manufacturing 6.2 Focus on developing technologically advanced vaccines such as DNA vaccines Chapter 7 Company Profiles 7.1 Boehringer Ingelheim 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 GlaxoSmithKline plc 7.2.1 Company Overview

Transparency Market Research

8

U.S. Vaccine Market

7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 Merck & Co., Inc. 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Novartis International AG 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Pfizer, Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments 7.6 Sanofi SA 7.6.1 Company Overview

Transparency Market Research

9

U.S. Vaccine Market

7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Zoetis, Inc. 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments

About Us Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical

forecasts,

competitive

landscape,

detailed

segmentation,

key

trends,

and

recommendations.

Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

Transparency Market Research

10

strategic